Johannes Beeslaar

Pfizer R&D UK Limited, Marlow International, Parkway
Marlow, ENG SL71YL, United Kingdom

Last Updated: 09/26/2026

Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 9 publications

Erratum to "Randomized trial showing persistence of hSBA titers elicited by a pentavalent meningococcal MenABCWY vaccine for up to 4 years following a primary series and safety and immunogenicity of a booster dose" [Vaccine 43 (2025) 126469].

Erratum to "Randomized trial showing persistence of hSBA titers elicited by a pentavalent meningococcal MenABCWY vaccine for up to 4 years following a primary series and safety and immunogenicity of a booster dose" [Vaccine 43 (2025) 126469].

Journal: Vaccine
Published: July 09, 2026

Randomized trial showing persistence of hSBA titers elicited by a pentavalent meningococcal MenABCWY vaccine for up to 4 years following a primary series and safety and immunogenicity of a booster dose.

Randomized trial showing persistence of hSBA titers elicited by a pentavalent meningococcal MenABCWY vaccine for up to 4 years following a primary series and safety and immunogenicity of a booster dose.

Journal: Vaccine
Published: April 30, 2024

Modeling persistence of hSBA titers over time following a primary series and a booster dose of MenB-FHbp.

Modeling persistence of hSBA titers over time following a primary series and a booster dose of MenB-FHbp.

Journal: Vaccine
Published: December 29, 2022

Safety data from the MenB-FHbp clinical development program in healthy individuals aged 10 years and older.

Safety data from the MenB-FHbp clinical development program in healthy individuals aged 10 years and older.

Journal: Vaccine
Published: November 16, 2020

Sex, Age, and Race Effects on Immunogenicity of MenB-FHbp, A Bivalent Meningococcal B Vaccine: Pooled Evaluation of Clinical Trial Data.

Sex, Age, and Race Effects on Immunogenicity of MenB-FHbp, A Bivalent Meningococcal B Vaccine: Pooled Evaluation of Clinical Trial Data.

Journal: Infectious diseases and therapy
Published: April 08, 2020

MenB-FHbp Vaccine Protects Against Diverse Meningococcal Strains in Adolescents and Young Adults: Post Hoc Analysis of Two Phase 3 Studies.

MenB-FHbp Vaccine Protects Against Diverse Meningococcal Strains in Adolescents and Young Adults: Post Hoc Analysis of Two Phase 3 Studies.

Journal: Infectious diseases and therapy
Published: October 30, 2019

Persistence and 4-year boosting of the bactericidal response elicited by two- and three-dose schedules of MenB-FHbp: A phase 3 extension study in adolescents.

Persistence and 4-year boosting of the bactericidal response elicited by two- and three-dose schedules of MenB-FHbp: A phase 3 extension study in adolescents.

Journal: Vaccine
Published: February 16, 2018

Clinical data supporting a 2-dose schedule of MenB-FHbp, a bivalent meningococcal serogroup B vaccine, in adolescents and young adults.

Clinical data supporting a 2-dose schedule of MenB-FHbp, a bivalent meningococcal serogroup B vaccine, in adolescents and young adults.

Journal: Vaccine
Published: December 28, 2017

A phase 3, randomized, active-controlled study to assess the safety and tolerability of meningococcal serogroup B vaccine bivalent rLP2086 in healthy adolescents and young adults.

A phase 3, randomized, active-controlled study to assess the safety and tolerability of meningococcal serogroup B vaccine bivalent rLP2086 in healthy adolescents and young adults.

Journal: Vaccine
Published: August 05, 2015
Showing 1-9 of 9

Last Updated: 09/26/2026